August 1, 2011
A critical eye on Infuse use studies
A leading spine journal is casting a critical eye on industry-supported research that has led to widespread use of Medtronic's controversial bone growth product Infuse. The June 2011 issue of Spine Journal carries a strongly worded editorial about the trial designs, reporting bias, and peer review shortfalls that the authors say have promoted the product's widespread use, with "eventual life-threatening complications and deaths."
Free Daily News
- Large-scale studies link preoperative cognition to delirium risk, reveal its deadly toll after surgery
- Socioeconomic deprivation linked to lower fitness before surgery, UK study finds
- Perioperative medication decisions need individualized risk-benefit approach
- FDA: National IV saline shortage over after years of strained supply
- FDA announces Class 1 recall for Draeger breathing filters
- Hospital CEO departures surge, boards turn to interim leadership
- Study: Attire shapes patient trust, perceptions
- ASC drill success hinges on preparation, adaptability, clear roles
- Robotic surgery shows better outcomes in select emergency colorectal cases, poised for wider use
- 5 costly mistakes to avoid when building an ASC
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement